Showing results (11-20 of 26) with videos related to
Sort By:
Pageof 3
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 1991
Cardiac disturbances during the administration of taxolE K Rowinsky, W P McGuire, T Guarnieri, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 1, 1997
New drugs in non-Hodgkin's lymphomaS G Arbuck, J M Sorensen, M C Christian, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 3, 2001
Clinical trial designs for cytostatic agents: are new approaches needed?E L Korn, S G Arbuck, J M Pluda, et al.Seminars in Oncology|April 1, 1997
Promising new agents under development by the Division of Cancer Treatment, Diagnosis, and Centers of the National Cancer InstituteM C Christian, J M Pluda, P T Ho, et al.The New England Journal of Medicine|November 30, 1995
The National Cancer Institute audit of the National Surgical Adjuvant Breast and Bowel Project Protocol B-06M C Christian, M S McCabe, E L Korn, et al.Investigational New Drugs|January 1, 1995
Cutaneous manifestations of Taxol therapyC J Link, G A Sarosy, E C Kohn, et al.Blood|March 1, 1994
Flexible granulocyte colony-stimulating factor dosing in ovarian cancer patients who receive dose-intense taxol therapyC J Link, A Bicher, E C Kohn, et al.Investigational New Drugs|February 1, 1993
Chloroquinoxaline sulfonamide: a sulfanilamide antitumor agent entering clinical trialsJ S Fisherman, B L Osborn, H G Chun, et al.Journal of the National Cancer Institute|August 2, 1989
4-Ipomeanol: a novel investigational new drug for lung cancerM C Christian, R E Wittes, B Leyland-Jones, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 1, 1991
Dose-escalation study of carboplatin (day 1) and cisplatin (day 3): tolerance and relation to leukocyte and buccal cell platinum--DNA adductsI Gill, F M Muggia, P M Terheggen, et al.Pageof 3